Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lynparza's Wider Prospects Boosted By Late-Stage Breast Cancer Study

Executive Summary

Hopes for wider use of AstraZeneca Lynparza (olaparib) were boosted by Phase III data showing improved survival rates in patients with a certain type of breast cancer who used the PARP inhibitor compared with chemotherapy alone.

You may also be interested in...



A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck

AstraZeneca agreed to partner two important oncology assets – Lynparza and selumetinib – with Merck after disappointing Imfinzi MYSTIC data. Merck will pay $1.6bn up front to get its hands on a PARP inhibitor, even though it previously owned one.

AstraZeneca's OlympiAD Trial Kick-Starts PARP In Breast Cancer

The OlympiAD monotherapy study paves the way for AstraZeneca's Lynparza in breast cancer, as well as other PARP inhibitors down the line, but the ASCO presentation raises questions about trial design and whether combinations are needed to boost efficacy.

It's Not All About IO: Seven Drugs To Watch At ASCO

Biomedtracker's review of ASCO abstracts revealed several drugs to watch outside of the immuno-oncology space at the annual cancer conference in Chicago, including market-expanding data for Roche's Perjeta and J&J's Zytiga, and Phase III data for AstraZeneca's PARP inhibitor Lynparza in breast cancer.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel